Clinical significance of aberrant DNA methylation in childhood acute lymphoblastic leukemia

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Childhood acute lymphoblastic leukemia (ALL) is a complex disease with varying clinical outcomes.
• Epigenetic modifications, such as gene methylation, are increasingly recognized as important factors in cancer development and progression.
• Understanding the methylation profiles in ALL may offer insights into disease subtypes and risk stratification.

Purpose of the Study:

• To investigate the association between gene methylation profiles and clinicopathological features in childhood acute lymphoblastic leukemia (ALL).
• To determine if specific gene methylation patterns correlate with patient age, leukemia immunophenotype (T-ALL vs. precursor B-ALL), and risk classification.

Main Methods:

• Analysis of methylation status for multiple genes (MGMT, p16, p15, SHP1, DAPK) in ninety-five patients with childhood ALL.
• Statistical analysis to correlate methylation status with clinicopathological data including age, immunophenotype, and risk group.

Main Results:

• Methylation of MGMT and p16 genes was associated with higher patient age.
• Methylation of p15 and SHP1 genes was more frequent in T-ALL compared to precursor B-ALL.
• DAPK gene methylation was more prevalent in precursor B-ALL.
• Patients with methylation of multiple genes were more likely to have a T-cell phenotype and be classified as medium/high risk.

Conclusions:

• Gene methylation status is significantly associated with distinct clinicopathological features in childhood ALL.
• Specific methylation patterns may help differentiate ALL subtypes and identify patients at higher risk.
• These findings highlight the potential role of epigenetics in the biology and clinical management of childhood ALL.